Capricor Therapeutics
CAPR
34 hedge funds and large institutions have $18.9M invested in Capricor Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 3 closing their positions.
70% more call options, than puts
Call options by funds: $574K | Put options by funds: $338K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
51% more capital invested
Capital invested by funds: $12.5M → $18.9M (+$6.39M)
11.09% more ownership
Funds ownership: 10.39% → 21.48% (+11%)
6% more funds holding
Funds holding: 32 → 34 (+2)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$15.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$453K |
| 3 |
Citigroup
New York
|
+$346K |
| 4 |
Millennium Management
New York
|
+$252K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$150K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$294K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$167K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$139K |
| 4 |
Jane Street
New York
|
-$63.4K |
| 5 |
Morgan Stanley
New York
|
-$58.7K |
CAPR Hedge Fund Activity: Q3 2023 in Review
34 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2023, worth a combined $18.9M — up 51% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CAPR positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $15.7M. The largest seller was BlackRock, cutting an estimated $294K.
- 34 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2023, up from 32 in Q2 2023.
- Funds reported $18.9M of Capricor Therapeutics stock for Q3 2023, up 51% quarter-over-quarter.
- 5 funds opened new Capricor Therapeutics positions in Q3 2023 and 3 closed out, a net change of +2 holders.
- The largest Capricor Therapeutics buyer in Q3 2023 was Highbridge Capital Management, an estimated $15.7M added.
- The largest Capricor Therapeutics seller in Q3 2023 was BlackRock, an estimated $294K sold.
Based on aggregated 13F filings for Q3 2023.